Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Epimmune Inc.
San Diego, California, United States
- Ownership
- Private
- Employees
- ~55
- Development stage
- Other
01
Overview
Epimmune developed peptide-based immunotherapies targeting cancer and infectious diseases. Its lead program EP2101 reached Phase II for non-small cell lung cancer before the company merged into IDM Pharma. The company also led a major NIH-backed effort to develop an HIV vaccine using its proprietary epitope technologies. Most clinical assets were discontinued or outlicensed following mergers/acquisitions.
- Therapeutic areas
- OncologyCardiovascularInfectious Diseases
- Modalities
- Peptide-based vaccines/epitopesImmunostimulantsSmall molecules
- Industry
- Biotech
02
Partnerships
Rhein Biotech – research agreement combining PADRE® technology with Rhein’s platformsBavarian Nordic – partnered on NIH-funded HIV vaccine projectSRI International & Althea Technologies – collaborators on HIV vaccine contract
Beyond the preview
Go deeper on Epimmune Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epimmune Inc..